Incidence, Prevalence, and Lifetime Risk Estimates of HF in the US
Key Points
- Approximately 6.7 million Americans over 20 years of age have HF, and the prevalence is expected to rise to 8.5 million Americans by 2030.
- The lifetime risk of HF has increased to 24%; approximately 1 in 4 persons will develop HF in their lifetime.
- The prevalence rate of HF among US adults is approximately 1.9% to 2.6% for the overall population and is higher among older patients. The prevalence rate is expected to increase to 8.5% among 65- to 70-year-olds.
- The prevalence of HF with preserved ejection fraction (HFpEF) across populations is increasing, with significant differences by race and ethnicity, and men experience a higher lifetime risk HFpEF.
- Approximately 33% of the US adult population without known symptomatic HF is at-risk for HF (Stage A HF) and 24%34% have pre-HF (Stage B HF). The risk of developing HF in individuals with obesity and hypertension has increased.
